{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T17:44:42Z","timestamp":1742924682965,"version":"3.40.3"},"publisher-location":"Cham","reference-count":27,"publisher":"Springer International Publishing","isbn-type":[{"type":"print","value":"9783031210532"},{"type":"electronic","value":"9783031210549"}],"license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023]]},"DOI":"10.1007\/978-3-031-21054-9_8","type":"book-chapter","created":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T13:02:55Z","timestamp":1678971775000},"page":"195-206","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Reverse Engineering Drugs: Lorcaserin as an Example"],"prefix":"10.1007","author":[{"given":"Tiffany","family":"Schwasinger-Schmidt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheldon H.","family":"Preskorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,17]]},"reference":[{"key":"8_CR1","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.nbd.2013.05.002","volume":"61","author":"DJ Nutt","year":"2014","unstructured":"Nutt DJ, Attridge J. CNS drug development in Europe\u2014past progress and future challenges. Neurobiol Dis. 2014;61:6\u201320.","journal-title":"Neurobiol Dis"},{"key":"8_CR2","unstructured":"National Institute of Health. Mental Health Information. 2019. Accessed at https:\/\/www.nimh.nih.gov\/health\/statistics\/mental-illness"},{"issue":"4","key":"8_CR3","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1002\/ana.24897","volume":"81","author":"CL Gooch","year":"2017","unstructured":"Gooch CL, Pracht E, Borenstein AR. The burden of neurological disease in the United States: a summary report and call to action. Ann Neurol. 2017 Apr;81(4):479\u201384. https:\/\/doi.org\/10.1002\/ana.24897.","journal-title":"Ann Neurol"},{"issue":"2","key":"8_CR4","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1001\/jamaneurol.2020.4152","volume":"78","author":"GBD 2017 US Neurological Disorders Collaborators","year":"2021","unstructured":"GBD 2017 US Neurological Disorders Collaborators. Burden of neurological disorders across the US From 1990\u20132017: a global burden of disease study. JAMA Neurol. 2021;78(2):165\u201376. https:\/\/doi.org\/10.1001\/jamaneurol.2020.4152.","journal-title":"JAMA Neurol"},{"issue":"7","key":"8_CR5","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/nrd2094","volume":"6","author":"MN Pangalos","year":"2007","unstructured":"Pangalos MN, Schechter LE, Hurko O. Drug development for CNS disorders: strategies for balancing risk and reducing attrition. Nat Rev Drug Discov. 2007;6(7):521\u201332.","journal-title":"Nat Rev Drug Discov"},{"key":"8_CR6","doi-asserted-by":"publisher","unstructured":"Kaitin KI. Deconstructing the drug development process: the new face of innovation. Clin Pharmacol Ther. 2010;87(3):356\u201361. https:\/\/doi.org\/10.1038\/clpt.2009.293. Epub 2010 Feb 3. Erratum in: Clin Pharmacol Ther. 2011;89(1):148. PMID: 20130565; PMCID: PMC2953249.","DOI":"10.1038\/clpt.2009.293"},{"key":"8_CR7","doi-asserted-by":"publisher","unstructured":"Mohs RC, Greig NH. Drug discovery and development: role of basic biological research. Alzheimer\u2019s Dement (N Y). 2017;3(4):651\u2013657. Published 2017 Nov 11. https:\/\/doi.org\/10.1016\/j.trci.2017.10.005.","DOI":"10.1016\/j.trci.2017.10.005"},{"issue":"5","key":"8_CR8","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1097\/PRA.0000000000000258","volume":"23","author":"S Preskorn","year":"2017","unstructured":"Preskorn S. Psychiatric and central nervous system drugs developed over the last decade: what are the implications for the field? J Psychiatr Pract. 2017;23(5):352\u201360.","journal-title":"J Psychiatr Pract"},{"issue":"6","key":"8_CR9","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1097\/01.pra.0000456594.66363.6f","volume":"20","author":"SH Preskorn","year":"2014","unstructured":"Preskorn SH. CNS drug development: lessons from the development of ondansetron, aprepitant, ramelteon, varenicline, lorcaserin, and suvorexant. Part I. J Psychiatr Pract\u00ae. 2014;20(6):460\u20135.","journal-title":"J Psychiatr Pract\u00ae"},{"issue":"9\u201310","key":"8_CR10","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.drudis.2009.02.008","volume":"14","author":"H Zhao","year":"2009","unstructured":"Zhao H, Guo Z. Medicinal chemistry strategies in follow-on drug discovery. Drug Discovery Today. 2009;14(9\u201310):516\u201322. ISSN 1359-6446. https:\/\/doi.org\/10.1016\/j.drudis.2009.02.008.","journal-title":"Drug Discovery Today"},{"key":"8_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0079-6468(08)70080-8","volume":"40","author":"BD Roth","year":"2002","unstructured":"Roth BD. The discovery and development of atorvastatin, a potent novel Hypolipidemic agent. Progr Med Chem. 2002;40:1\u201322. https:\/\/doi.org\/10.1016\/S0079-6468(08)70080-8.","journal-title":"Progr Med Chem"},{"key":"8_CR12","doi-asserted-by":"publisher","unstructured":"Cameron DA, Stein S. Drug insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer. Nat Clin Pract Oncol. 2008;5(9):512\u201320. https:\/\/doi.org\/10.1038\/ncponc1156. Epub 2008 Jul 1.","DOI":"10.1038\/ncponc1156"},{"issue":"24","key":"8_CR13","doi-asserted-by":"publisher","first-page":"7456","DOI":"10.1158\/1078-0432.CCR-08-3041","volume":"15","author":"V Gandhi","year":"2009","unstructured":"Gandhi V, Burger JA. Bendamustine in B-cell malignancies: the new 46-year-old kid on the block. Clin Cancer Res. 2009;15(24):7456\u201361. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-3041.","journal-title":"Clin Cancer Res"},{"key":"8_CR14","doi-asserted-by":"publisher","unstructured":"Gale JD, Houghton LA. Alpha 2 Delta (\u03b1(2)\u03b4) Ligands, gabapentin and pregabalin: What is the evidence for potential use of these ligands in irritable bowel syndrome. Front Pharmacol. 2011;2:28. Published 2011 Jun 9. https:\/\/doi.org\/10.3389\/fphar.2011.00028.","DOI":"10.3389\/fphar.2011.00028"},{"key":"8_CR15","doi-asserted-by":"publisher","unstructured":"Higgins GA, Fletcher PJ, Shanahan WR. Lorcaserin: a review of its preclinical and clinical pharmacology and therapeutic potential. Pharmacol Ther. 2020;205. https:\/\/doi.org\/10.1016\/j.pharmthera.2019.107417.","DOI":"10.1016\/j.pharmthera.2019.107417"},{"key":"8_CR16","doi-asserted-by":"publisher","unstructured":"Bai B, Wang Y. The use of lorcaserin in the management of obesity: a critical appraisal. Drug Des Devel Ther. 2010;5:1\u20137. Published 2010 Dec 20. https:\/\/doi.org\/10.2147\/DDDT.S11945.","DOI":"10.2147\/DDDT.S11945"},{"issue":"1","key":"8_CR17","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jand.2012.08.028","volume":"113","author":"LE Miller","year":"2013","unstructured":"Miller LE. Lorcaserin for weight loss: insights into US Food and Drug Administration approval. J Acad Nutr Diet. 2013;113(1):25\u201330.","journal-title":"J Acad Nutr Diet"},{"key":"8_CR18","doi-asserted-by":"publisher","first-page":"108155","DOI":"10.1016\/j.neuropharm.2020.108155","volume":"177","author":"T Sharp","year":"2020","unstructured":"Sharp T, Barnes NM. Central 5-HT receptors and their function; present and future. Neuropharmacology. 2020;177:108155.","journal-title":"Neuropharmacology"},{"key":"8_CR19","doi-asserted-by":"crossref","unstructured":"Fletcher PJ, Higgins GA. Serotonin and reward-related behavior: focus on 5-HT 2C receptors. In: 5-HT2C receptors in the pathophysiology of CNS disease. Humana Press, Totowa; 2011, pp. 293\u2013324.","DOI":"10.1007\/978-1-60761-941-3_15"},{"issue":"5","key":"8_CR20","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/cob.12159","volume":"6","author":"FL Greenway","year":"2016","unstructured":"Greenway FL, et al. Safety and tolerability review of lorcaserin in clinical trials. Clin Obesity. 2016;6(5):285\u201395.","journal-title":"Clin Obesity"},{"issue":"1","key":"8_CR21","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/clpt.2013.204","volume":"95","author":"GW Kim","year":"2014","unstructured":"Kim GW, Lin JE, Blomain ES, Waldman SA. Anti obesity pharmacotherapy: new drugs and emerging targets. Clin Pharmacol Ther. 2014;95(1):53\u201366. https:\/\/doi.org\/10.1038\/clpt.2013.204.","journal-title":"Clin Pharmacol Ther"},{"key":"8_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/164_2018_167","volume-title":"Antidepressants. Handbook of experimental pharmacology","author":"TE Schwasinger-Schmidt","year":"2018","unstructured":"Schwasinger-Schmidt TE, Macaluso M. Other antidepressants. In: Macaluso M, Preskorn S, editors. Antidepressants. Handbook of experimental pharmacology, vol. 250. Cham: Springer; 2018. https:\/\/doi.org\/10.1007\/164_2018_167."},{"key":"8_CR23","doi-asserted-by":"publisher","unstructured":"Kianirad Y, Simuni T. Pimavanserin, a novel antipsychotic for management of Parkinson\u2019s disease psychosis. Expert Rev Clin Pharmacol. 2017;10(11):1161\u20131168. doi: https:\/\/doi.org\/10.1080\/17512433.2017.1369405. Epub 2017 Oct 17.","DOI":"10.1080\/17512433.2017.1369405"},{"issue":"2","key":"8_CR24","doi-asserted-by":"publisher","first-page":"175","DOI":"10.4103\/0976-500X.130158","volume":"5","author":"DB Brashier","year":"2014","unstructured":"Brashier DB, Sharma AK, Dahiya N, Singh SK, Khadka A. Lorcaserin: a novel antiobesity drug. J Pharmacol Pharmacother. 2014;5(2):175\u20138. https:\/\/doi.org\/10.4103\/0976-500X.130158.","journal-title":"J Pharmacol Pharmacother"},{"issue":"11","key":"8_CR25","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1586\/erc.09.123","volume":"7","author":"HE Bays","year":"2009","unstructured":"Bays HE. Lorcaserin and adiposopathy: 5-HT2c agonism as a treatment for \u2018sick fat\u2019 and metabolic disease. Expert Rev Cardiovasc Ther. 2009;7(11):1429\u201345.","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"11","key":"8_CR26","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1021\/cn100059u","volume":"1","author":"CR Hopkins","year":"2010","unstructured":"Hopkins CR. ACS chemical neuroscience molecule spotlight on lorcaserin. ACS Chem Neurosci. 2010;1(11):718\u20139.","journal-title":"ACS Chem Neurosci"},{"key":"8_CR27","doi-asserted-by":"publisher","unstructured":"Caban A, Pisarczyk K, Kopacz K, Kapu\u015bniak A, Toumi M, R\u00e9muzat C, Kornfeld A. Filling the gap in CNS drug development: evaluation of the role of drug repurposing. J Mark Access Health Policy. 2017;5(1):1299833. https:\/\/doi.org\/10.1080\/20016689.2017.1299833. PMID: 28473889; PMCID: PMC5405562.","DOI":"10.1080\/20016689.2017.1299833"}],"container-title":["Advances in Neurobiology","Drug Development in Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-031-21054-9_8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T13:04:34Z","timestamp":1678971874000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-031-21054-9_8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"ISBN":["9783031210532","9783031210549"],"references-count":27,"URL":"https:\/\/doi.org\/10.1007\/978-3-031-21054-9_8","relation":{},"ISSN":["2190-5215","2190-5223"],"issn-type":[{"type":"print","value":"2190-5215"},{"type":"electronic","value":"2190-5223"}],"subject":[],"published":{"date-parts":[[2023]]},"assertion":[{"value":"17 March 2023","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}